Silvia Kim-Ratto

Silver Spring
Spring, AB, Romania

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Monocyte Correlates of Neurocognitive Impairment in Chronic HIV infection, Early, Persistent Changes with Antiretroviral Therapy.

Monocyte Correlates of Neurocognitive Impairment in Chronic HIV infection, Early, Persistent Changes with Antiretroviral Therapy.

Journal: JCI insight
Published: August 27, 2026

Monocyte and CD4+ T-cell antiviral and innate responses associated with HIV-1 inflammation and cognitive impairment.

Monocyte and CD4+ T-cell antiviral and innate responses associated with HIV-1 inflammation and cognitive impairment.

Journal: AIDS (London, England)
Published: June 30, 2020

Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART.

Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART.

Journal: AIDS (London, England)
Published: November 26, 2019

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.

Journal: Journal of virology
Published: July 02, 2018

The US Military Commitment to Vaccine Development: A Century of Successes and Challenges.

The US Military Commitment to Vaccine Development: A Century of Successes and Challenges.

Journal: Frontiers in immunology
Published: May 15, 2018

Characterization of Cellular Immune Responses in Thai Individuals With and Without HIV-Associated Neurocognitive Disorders.

Characterization of Cellular Immune Responses in Thai Individuals With and Without HIV-Associated Neurocognitive Disorders.

Journal: AIDS research and human retroviruses
Published: May 09, 2018

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.

Journal: The Journal of infectious diseases
Published: May 15, 2017

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.

Journal: The Journal of infectious diseases
Published: October 11, 2016

Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection.

Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection.

Journal: PLoS pathogens
Published: February 02, 2016

HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.

HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.

Journal: Expert review of vaccines
Published: January 28, 2016

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Journal: Nature medicine
Published: November 25, 2015

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

Journal: The Journal of infectious diseases
Published: August 24, 2015
Showing 1-12 of 22

Last Updated: 09/26/2026